HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Secretary Sebelius’ override appears to set a precedent of HHS intervention in an FDA product review.
You may also be interested in...
Panel Of Former US FDA Commissioners Make Renewed Call For Independent Agency
Former FDA heads reflected on instances when they experienced pressure from their higher-ups; speakers also offered praise for the job Commissioner Scott Gottlieb is doing at the agency.
Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price
Democrats test US FDA commissioner nominee's willingness to defend agency independence during confirmation hearing and probe potential conflicts of interest.
Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be a lasting problem.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: